Pito Chickering

Joel explained the mix decline reflects new admits entering at a lower QHP mix, a dynamic expected to persist into next year and drive the guided commercial-mix headwinds.

Joel said capacity utilization runs in the high 50s versus a pre-COVID peak near 65%, but declined to give a clean incremental margin, noting it depends on patient payer mix.

CEO reframed G&A as part of total cost optimization. 5-year total cost CAGR is 2.6%. AI and tech investments flow through G&A but drive efficiency in patient care costs and revenue operations. Full-year total cost guide of 1.25-2.25% stands.

CFO estimated about half of Fresenius transfers arrived by end of Q1, other half expected in Q2. Normalized treatments per day at ~40bps positive now, expected to grow over the year toward the 50-75bps full-year average.

CFO bridged from Q1 to full year via two factors: normal timing variability inflating Q1, and expected commercial mix decline from premium tax credit expiration creating RPT pressure through the year. Confirmed no negative mix impact seen through April yet.

CFO said international growth is approximately 50/50 M&A and organic, with margins expected to improve as fixed overhead is leveraged. Contributing about 1 point to enterprise OI growth, consistent with recent years.

CFO expects flattish new starts with similar commercial mix to recent years. New patients historically have higher commercial mix which migrates to Medicare over time. Only callout is potential HICS-related change.

CFO attributed the slowdown to natural maturation of the business with less room for margin expansion. Not expecting IKC to become a high-margin business; $20M annual contribution to OI growth is a comfortable target.

CFO explained the main timing shift was pulling 2024 plan year revenue into Q2 rather than the back half. IKC timing remains difficult to predict as it depends on when payers and the government release performance data.

CFO noted USRDS data is limited (only Q1 2025 available, prevalence data less reliable). CEO said adjusting for ~1,600 patients impacted by PD and cyber, field intelligence shows no meaningful market share shift.

CFO said no IOTA impact. Volume came in largely as expected with slightly more missed treatment pressure. Admissions running in normal post-COVID band. Mortality down vs Q1 but that is seasonal flu normalization, no new trend to call out.

CFO identified RPT and IKC timing as the main range drivers. For volume, expect Q4 year-over-year absolute treatment volume growth of positive 20-30bps, driven by the day mix tailwind reversing Q3's headwind.

CFO attributed guidance maintenance primarily to patient care cost outperformance (labor productivity) plus approximately $10 million international beat, largely nonrecurring.

Admits ex-cyber showed normal YoY growth. Mortality remains elevated vs pre-COVID but consistent with prior year. CEO emphasized they are not seeing GLP-1/SGLT2 impact on admits.

CFO pointed to typical first-half weakness, cyber recovery, and significantly better cash taxes in the back half as the primary drivers of the bridge.

CEO was blunt about undisciplined competitors in value-based care. DaVita maintaining financial discipline and severing arrangements with doctors unwilling to change practice patterns.

CFO confirmed strong Q1 admits, supporting the hypothesis that Q4 weakness was normal variability. Mortality was elevated due to flu, with limited post-flu visibility due to data lag.

CFO noted broad-based international strength and raised full-year international OI by approximately $10 million above the previously guided $50 million year-over-year growth.

Management argued SGLT2 impact on patient population is unlikely given low CKD prevalence in low teens and mid-sixties adherence. New-to-dialysis admits were flattish in Q4, first non-positive quarter in eight.

CFO clarified they use GAAP accrual accounting but are prudent on timing. Noted progress on MA revenue estimation but more conservative on CKCC fee-for-service program.

CFO clarified that while PD admissions normalized, the 350 lost patients represent a permanent 15-20bps volume headwind in 2025, plus 20bps from leap year.

Filton acknowledged the shift is permanent and described ASC ownership plus OR and equipment investment as the response.

UHS does not track emergent versus elective, so Filton gave the inpatient/outpatient split only and credited robotics and imaging investment.

Miller cited Hippocratic AI investment providing front-seat access to new solutions. Post-discharge AI calls already reducing headcount. AI-based rounding technology being tested for quality and malpractice impact. Behavioral intake AI to improve referral response times. Acknowledged difficult to pinpoint exact dollar impact.

Filton said ideal range is 2-3x, currently at low end for maximum flexibility. Don't expect leverage to go lower. Share repurchase continues as compelling investment. Not maintaining low leverage for one specific deal but wants capacity for unpredictable M&A opportunities.

Filton confirmed outpatient growing faster than inpatient in Q2, reversing Q1 trend. Targeting larger share of the outpatient pie that payers are increasingly directing behavioral spend toward.

Filton outlined multiple mitigation levers: shifting behavioral programming away from Medicaid-centric programs, cost-cutting, potential new DPP programs, and possible legislative changes before 2028.

Filton attributed supply cost improvement partly to medical/respiratory patient mix shift but also to active contractual pricing management and product replacements.

Filton disclosed tentative Pavilion settlement pending court approval with substantial commercial insurance remaining for 2020 year. Cumberland cases moving slowly through appeals.

Filton confirmed target leverage in high 2x range; current sub-2x creates room for incremental borrowing to fund buybacks beyond the $600-800M annual range.

Filton described ongoing portfolio management as standard practice, closures, consolidations, and retooling of underperforming facilities.

Kevin Lobo dismissed pull-forward thesis, sees it as core market share gains. Surgeons have no anxiety about a falloff in procedures. Continued strong demand entering Q4.

Jason Beach emphasized Stryker's capital categories are revenue-generating for hospitals. Kevin Lobo added that even large capital like Mako and ProCuity were very strong with a lot of outright purchases and strong orders rarely canceled.

Kevin confirmed pure organic performance. Communications/Oculon Light had phenomenal quarter. 1788 camera strong. Sports Medicine on fire with 6 shoulder products launched in 6-8 months.

Preston cited top-line flow-through plus favorable FX. Some spend discipline for tariff offsets limits full flow-through. Wider EPS range reflects tariff uncertainty.

Preston confirmed rental trend is structural as Mako scales, not a reflection of capital environment weakness. Rentals often convert to direct sales over time.

Preston noted varies by business but Q4 should represent the run rate based on current tariffs in place.

Kevin expects another year of double-digit growth in Medical, powered by Sage, emergency care, beds, stretchers, Vocera, LIFEPAK.

Glenn confirmed Spine not material to overall numbers, seasonality unchanged from 2024 to 2025.

Marks listed three qualitative drivers (volume, cost, management team) but did not provide the quantified core EBITDA bridge that was asked for.

Mike reiterated three swing factors: $600-900M exchange headwind, $250-450M supplemental payment decline (excluding potential grandfathered approvals), and $400M resiliency offset. Confirmed core growth above long-term guidance range.

Mike bridged Q4: hurricane recovery ($100M) offset by $120M supplemental payment decline. Implied growth rate ~7%. Sequential Q3-to-Q4 in line with historical trends.

Mike clarified H1 had $180M net benefit vs $130M decline expected in H2, entirely in Q4 due to non-repeating one-time payments. Tennessee cash expected to flow materially in Q3.

Sam explained fixed-cost operating leverage model, turnover improvements, contract labor declines, and record engagement scores. Confirmed labor market is stable.

Mike Marks provided clear quarterly flow and full-year bridge. Acknowledged $400M 2024 benefit was above expectations due to one-time state payments.

Davis emphasized the rigorous NY approval as a quality signal and said Quest is pacing commercial investment to reimbursement.

Sam disclosed test per req now north of 4.2 vs pre-COVID 3.5-4.0. Driven by clinical guidelines, broader test menu, AD-Detect, wellness. Expects continued improvement but slowing pace.

Sam declined to give specific tariff figure but confirmed manageable within guidance. 80% of spend under contract. Jim reiterated 80% U.S.-sourced, <1% China.

Sam confirmed 80% U.S.-sourced, 70-80% under contract. Jim described healthy M&A funnel including Fresenius deal for 200,000+ dialysis patients.

Jim confirmed net gain of over 1 million lives from payer changes. Access expanded to over 90% of in-network US lives. Typical 25-30% of health plan contracts renew annually.

Chopra confirmed the Q4 approval expectation and European experience but would not characterize trial success ahead of the TCT presentation.

Larry Wood pushed back on specific timing speculation, noting CMS controls timeline entirely. Expects asymptomatic approval to be a catalyst for CMS to reopen NCD.

Daveen noted training sites booked several months out. Demand exceeds capacity. Goal is to grow into a significant portion of the 850 TAVR centers over many years.

Daveen confirmed starting from ~50 trial sites and expanding linearly. Training programs are continuous but no specific count given beyond trial base.

Daveen declined to provide exact split but confirmed Europe still larger than U.S. with U.S. coming online as second major driver.